AAAAAA
Results: 51-73/73
Authors:
Malloy, MJ
Kane, JP
Citation: Mj. Malloy et Jp. Kane, Disorders involving deficiencies of lipoproteins that contain B apolipoproteins, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 863-877
Authors:
Lean, MEJ
Citation: Mej. Lean, Obesity and eating disorders, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 881-895
Authors:
Duell, PB
Citation: Pb. Duell, Diabetes mellitus, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 897-929
Authors:
Kissebah, AH
Krakower, GR
Citation: Ah. Kissebah et Gr. Krakower, Endocrine disorders, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 931-941
Authors:
Short, CD
Durrington, PN
Citation: Cd. Short et Pn. Durrington, Renal disorders, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 943-966
Authors:
Tikkanen, MJ
Citation: Mj. Tikkanen, Sex hormones, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 967-984
Authors:
Miller, JP
Citation: Jp. Miller, Liver disease, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 985-1009
Authors:
Baraona, E
Lieber, CS
Citation: E. Baraona et Cs. Lieber, Alcohol, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1011-1036
Authors:
Muller-Wieland, D
Krone, W
Citation: D. Muller-wieland et W. Krone, Drug-induced effects, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1037-1048
Authors:
Markell, MS
Citation: Ms. Markell, Transplantation, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1049-1067
Authors:
Edwards, CM
Stacpoole, PW
Citation: Cm. Edwards et Pw. Stacpoole, Rare secondary dyslipidaemias, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1069-1098
Authors:
Bernini, F
Paoletti, R
Citation: F. Bernini et R. Paoletti, Treatment objectives, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1101-1109
Authors:
Connor, WE
Connor, SL
Citation: We. Connor et Sl. Connor, Lipid-lowering diets, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1111-1131
Authors:
Hunninghake, DB
Citation: Db. Hunninghake, Bile-acid sequestering agents (resins), LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1133-1144
Authors:
Gaw, A
Shepherd, J
Citation: A. Gaw et J. Shepherd, Fibric acid derivatives, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1145-1160
Authors:
Illingworth, DR
Citation: Dr. Illingworth, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1161-1179
Authors:
Walldius, G
Wahlberg, G
Citation: G. Walldius et G. Wahlberg, Nicotinic acid and its derivatives, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1181-1197
Authors:
Sirtori, CR
Citation: Cr. Sirtori, Probucol, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1199-1211
Authors:
Sampson, MJ
Betteridge, DJ
Citation: Mj. Sampson et Dj. Betteridge, Hyperlipidaemia and combination drug therapy, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1213-1229
Authors:
Reckless, JPD
Citation: Jpd. Reckless, Cost-benefit analysis of lipid-lowering management, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1231-1254
Authors:
Seidel, D
Citation: D. Seidel, Non-pharmacological procedures: treatment of severe hypercholesterolaemia in patients with coronary heart disease by means of heparin-induced extracorporeal low-density lipoprotein plasmapheresis, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1255-1266
Authors:
Suckling, K
Fears, R
Citation: K. Suckling et R. Fears, Future developments in drug therapy, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1267-1277
Authors:
West, R
Citation: R. West, Management of hyperlipidaemia in children, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1279-1284